U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C41H64O13
Molecular Weight 764.9391
Optical Activity UNSPECIFIED
Defined Stereocenters 20 / 20
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Digitoxin

SMILES

[H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]4CC[C@@]5(C)[C@]([H])(CC[C@]6([H])[C@]5([H])CC[C@]7(C)[C@H](CC[C@]67O)C8=CC(=O)OC8)C4

InChI

InChIKey=WDJUZGPOPHTGOT-XUDUSOBPSA-N
InChI=1S/C41H64O13/c1-20-36(46)29(42)16-34(49-20)53-38-22(3)51-35(18-31(38)44)54-37-21(2)50-33(17-30(37)43)52-25-8-11-39(4)24(15-25)6-7-28-27(39)9-12-40(5)26(10-13-41(28,40)47)23-14-32(45)48-19-23/h14,20-22,24-31,33-38,42-44,46-47H,6-13,15-19H2,1-5H3/t20-,21-,22-,24-,25+,26-,27+,28-,29+,30+,31+,33+,34+,35+,36-,37-,38-,39+,40-,41+/m1/s1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including http://www.medscape.com/viewarticle/842364

Digoxin is a cardiac glycoside derived from the purple foxglove flower. In 1785, the English chemist, botanist, and physician Sir William Withering published his findings that Digitalis purpurea could be used to treat cardiac dropsy (congestive heart failure; CHF). Digoxin has been in use for many years, but was not approved by the FDA for treatment of heart failure (HF) until the late 1990s. Another FDA indication for digoxin is atrial fibrillation (AF). Digoxin also has numerous off-label uses, such as in fetal tachycardia, supra-ventricular tachycardia, cor pulmonale, and pulmonary hypertension. Digitoxin inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). Digoxin also has Para sympathomimetic properties. By increasing vagal tone in the sinoatrial and atrioventricular (AV) nodes, it slows the heart rate and AV nodal conduction.

CNS Activity

Sources: doi/10.1002/clc.4960020211/pdf

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CRYSTODIGIN

Approved Use

In adults, digoxin is indicated for the treatment of mild to moderate heart failure and for the control of resting ventricular rate in patients with chronic atrial fibrillation. (1). In pediatric patients with heart failure, digoxin increases myocardial contractility
Diagnostic
CRYSTODIGIN

Approved Use

In adults, digoxin is indicated for the treatment of mild to moderate heart failure and for the control of resting ventricular rate in patients with chronic atrial fibrillation. (1). In pediatric patients with heart failure, digoxin increases myocardial contractility
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.76 ng/mL
0.25 mg 1 times / day steady-state, oral
dose: 0.25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: ETORICOXIB
DIGITOXIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1.32 ng/mL
0.25 mg 1 times / day steady-state, oral
dose: 0.25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DIGITOXIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
13.3 ng × h/mL
0.25 mg 1 times / day steady-state, oral
dose: 0.25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: ETORICOXIB
DIGITOXIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
12.5 ng × h/mL
0.25 mg 1 times / day steady-state, oral
dose: 0.25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DIGITOXIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
9.5 day
0.5 mg single, intravenous
dose: 0.5 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DIGITOXIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
7.4 day
0.5 mg single, oral
dose: 0.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIGITOXIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
9.7 day
0.5 mg single, oral
dose: 0.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIGITOXIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.1 mg 1 times / day multiple, oral
Studied dose
Dose: 0.1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.1 mg, 1 times / day
Sources:
healthy, 23 to 29 years
n = 10
Health Status: healthy
Age Group: 23 to 29 years
Sex: M
Population Size: 10
Sources:
Other AEs: Color blindness acquired...
Other AEs:
Color blindness acquired
Sources:
0.2 mg 2 times / day multiple, oral (mean)
Studied dose
Dose: 0.2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.2 mg, 2 times / day
Co-administed with::
digoxin(0.05 mg; 2 tablets per day)
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: heart failure
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Other AEs: Fatigue, Visual disorders NEC...
Other AEs:
Fatigue (53.1%)
Visual disorders NEC (53.1%)
Muscular weakness (45.8%)
Nausea (45.2%)
Anorexia (44.7%)
Psychic disorder NOS (36.3%)
Abdominal pain (36.3%)
Dizziness (33%)
Bad dreams (30.2%)
Headache (25.1%)
Diarrhoea (22.9%)
Vomiting (22.3%)
Pain retrosternal (5%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Color blindness acquired
0.1 mg 1 times / day multiple, oral
Studied dose
Dose: 0.1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.1 mg, 1 times / day
Sources:
healthy, 23 to 29 years
n = 10
Health Status: healthy
Age Group: 23 to 29 years
Sex: M
Population Size: 10
Sources:
Vomiting 22.3%
0.2 mg 2 times / day multiple, oral (mean)
Studied dose
Dose: 0.2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.2 mg, 2 times / day
Co-administed with::
digoxin(0.05 mg; 2 tablets per day)
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: heart failure
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Diarrhoea 22.9%
0.2 mg 2 times / day multiple, oral (mean)
Studied dose
Dose: 0.2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.2 mg, 2 times / day
Co-administed with::
digoxin(0.05 mg; 2 tablets per day)
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: heart failure
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Headache 25.1%
0.2 mg 2 times / day multiple, oral (mean)
Studied dose
Dose: 0.2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.2 mg, 2 times / day
Co-administed with::
digoxin(0.05 mg; 2 tablets per day)
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: heart failure
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Bad dreams 30.2%
0.2 mg 2 times / day multiple, oral (mean)
Studied dose
Dose: 0.2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.2 mg, 2 times / day
Co-administed with::
digoxin(0.05 mg; 2 tablets per day)
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: heart failure
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Dizziness 33%
0.2 mg 2 times / day multiple, oral (mean)
Studied dose
Dose: 0.2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.2 mg, 2 times / day
Co-administed with::
digoxin(0.05 mg; 2 tablets per day)
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: heart failure
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Abdominal pain 36.3%
0.2 mg 2 times / day multiple, oral (mean)
Studied dose
Dose: 0.2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.2 mg, 2 times / day
Co-administed with::
digoxin(0.05 mg; 2 tablets per day)
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: heart failure
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Psychic disorder NOS 36.3%
0.2 mg 2 times / day multiple, oral (mean)
Studied dose
Dose: 0.2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.2 mg, 2 times / day
Co-administed with::
digoxin(0.05 mg; 2 tablets per day)
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: heart failure
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Anorexia 44.7%
0.2 mg 2 times / day multiple, oral (mean)
Studied dose
Dose: 0.2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.2 mg, 2 times / day
Co-administed with::
digoxin(0.05 mg; 2 tablets per day)
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: heart failure
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Nausea 45.2%
0.2 mg 2 times / day multiple, oral (mean)
Studied dose
Dose: 0.2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.2 mg, 2 times / day
Co-administed with::
digoxin(0.05 mg; 2 tablets per day)
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: heart failure
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Muscular weakness 45.8%
0.2 mg 2 times / day multiple, oral (mean)
Studied dose
Dose: 0.2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.2 mg, 2 times / day
Co-administed with::
digoxin(0.05 mg; 2 tablets per day)
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: heart failure
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Pain retrosternal 5%
0.2 mg 2 times / day multiple, oral (mean)
Studied dose
Dose: 0.2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.2 mg, 2 times / day
Co-administed with::
digoxin(0.05 mg; 2 tablets per day)
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: heart failure
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Fatigue 53.1%
0.2 mg 2 times / day multiple, oral (mean)
Studied dose
Dose: 0.2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.2 mg, 2 times / day
Co-administed with::
digoxin(0.05 mg; 2 tablets per day)
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: heart failure
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Visual disorders NEC 53.1%
0.2 mg 2 times / day multiple, oral (mean)
Studied dose
Dose: 0.2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.2 mg, 2 times / day
Co-administed with::
digoxin(0.05 mg; 2 tablets per day)
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: heart failure
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [IC50 14.2 uM]
yes [IC50 36 uM]
Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Influence of drugs, implanted into the hypothalamus, on the water consumption of rats.
1968 Jan
[Acute digitalic poisoning].
1970 Feb
[Digitoxin-induced thrombocytopenia].
1993
Digitoxin medication and cancer; case control and internal dose-response studies.
2001
Adverse drug reaction monitoring--digitoxin overdosage in the elderly.
2001 Aug
Bidirectional tachycardia: two cases and a review.
2002 Aug
Heart failure drug digitoxin induces calcium uptake into cells by forming transmembrane calcium channels.
2008 Feb 19
Digitoxin elicits anti-inflammatory and vasoprotective properties in endothelial cells: Therapeutic implications for the treatment of atherosclerosis?
2009 Oct
Antiherpes activity of glucoevatromonoside, a cardenolide isolated from a Brazilian cultivar of Digitalis lanata.
2011 Oct
Digitoxin and a synthetic monosaccharide analog inhibit cell viability in lung cancer cells.
2012 Jan 1
Patents

Sample Use Guides

Age Oral Loading Dose, mcg/kg Premature: 20 - 30; Full-Term 25 - 35; 1 to 24 months 35 - 60; 2 to 5 years 30 - 45; 5 to 10 years 20 - 35; Over 10 years 10 - 15
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: digitoxin inhibits interaction of NFAT1 with the proximal c-MYC promoter
Unknown
Name Type Language
Digitoxin
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INN  
Official Name English
TRADIGAL
Common Name English
CRYSTODIGIN
Code English
DIGIMERCK
Common Name English
DIGITOXINUM [HPUS]
Common Name English
UNIDIGIN
Common Name English
CARD-20(22)-ENOLIDE, 3-((O-2,6-DIDEOXY-.BETA.-D-RIBO-HEXOPYRANOSYL-(1->4)-O-2,6-DIDEOXY-.BETA.-D-RIBO-HEXOPYRANOSYL-(1->4)-2,6-DIDEOXY-.BETA.-D-RIBO-HEXOPYRANOSYL)OXY)-14-HYDROXY-, (3.BETA.,5.BETA.)-
Common Name English
(3.BETA.,5.BETA.)-3-((O-2,6-DIDEOXY-.BETA.-D-RIBO-HEXOPYRANOSYL-(1->4)-O-2,6-DIDEOXY-.BETA.-D-RIBO-HEXOPYRANOSYL-(1->4)-2,6-DIDEOXY-.BETA.-D-RIBO-HEXOPYRANOSYL)OXY)-14-HYDROXYCARD-20(22)-ENOLIDE
Common Name English
DIGITALIN, CRYSTALLINE
Common Name English
DIGITOXIN [WHO-IP]
Common Name English
DIGITOXIN [MI]
Common Name English
DIGITOXIN [EP MONOGRAPH]
Common Name English
DIGITOXIN [JAN]
Common Name English
(3.BETA.,5.BETA.)-3-((O-2,6-DIDEOXY-.BETA.-D-RIBO-HEXAPYRANOSYL-(1->4)-2,6-DIDEOXY-.BETA.-D-RIBO-HEXOPYRANOSYL)OXY)-14-HYDROXYCARD-20(22)-ENOLIDE
Common Name English
DIGITOXOSIDE
Common Name English
Digitoxin [WHO-DD]
Common Name English
DIGITOXIN [USP IMPURITY]
Common Name English
DIGITOPHYLLIN
Common Name English
DIGITOXINUM
HPUS   WHO-IP LATIN  
Common Name English
GLUCODIGIN
Common Name English
DIGITOXIN [ORANGE BOOK]
Common Name English
DIGITOXIN [USP MONOGRAPH]
Common Name English
DIGITOXIN [HSDB]
Common Name English
DIGITOXIN [USP-RS]
Common Name English
DIGOXIN IMPURITY A [EP IMPURITY]
Common Name English
DIGITOXINUM [WHO-IP LATIN]
Common Name English
DIGITOXIN [VANDF]
Common Name English
digitoxin [INN]
Common Name English
NSC-7529
Code English
PURPURID
Common Name English
3.BETA.-((2,6-DIDEOXY-.BETA.-D-RIBO-HEXOPYRANOSYL-(1->4)-2,6-DIDEOXY-.BETA.-D-RIBO-HEXOPYRANOSYL-(1->4)-2,6-DIDEOXY-.BETA.-D-RIBO-HEXOPYRANOSYL)OXY)-14-HYDROXY-5.BETA.-CARD-20(22)-ENOLIDE
Systematic Name English
LANATOXIN
Common Name English
CRISTAPURAT
Common Name English
Classification Tree Code System Code
CFR 21 CFR 862.3300
Created by admin on Fri Dec 15 16:39:41 UTC 2023 , Edited by admin on Fri Dec 15 16:39:41 UTC 2023
WHO-VATC QC01AA04
Created by admin on Fri Dec 15 16:39:41 UTC 2023 , Edited by admin on Fri Dec 15 16:39:41 UTC 2023
FDA ORPHAN DRUG 205005
Created by admin on Fri Dec 15 16:39:41 UTC 2023 , Edited by admin on Fri Dec 15 16:39:41 UTC 2023
FDA ORPHAN DRUG 149601
Created by admin on Fri Dec 15 16:39:41 UTC 2023 , Edited by admin on Fri Dec 15 16:39:41 UTC 2023
NCI_THESAURUS C471
Created by admin on Fri Dec 15 16:39:41 UTC 2023 , Edited by admin on Fri Dec 15 16:39:41 UTC 2023
NCI_THESAURUS C78322
Created by admin on Fri Dec 15 16:39:41 UTC 2023 , Edited by admin on Fri Dec 15 16:39:41 UTC 2023
WHO-ATC C01AA04
Created by admin on Fri Dec 15 16:39:41 UTC 2023 , Edited by admin on Fri Dec 15 16:39:41 UTC 2023
LIVERTOX 306
Created by admin on Fri Dec 15 16:39:41 UTC 2023 , Edited by admin on Fri Dec 15 16:39:41 UTC 2023
FDA ORPHAN DRUG 149701
Created by admin on Fri Dec 15 16:39:41 UTC 2023 , Edited by admin on Fri Dec 15 16:39:41 UTC 2023
Code System Code Type Description
HSDB
215
Created by admin on Fri Dec 15 16:39:41 UTC 2023 , Edited by admin on Fri Dec 15 16:39:41 UTC 2023
PRIMARY
RXCUI
3403
Created by admin on Fri Dec 15 16:39:41 UTC 2023 , Edited by admin on Fri Dec 15 16:39:41 UTC 2023
PRIMARY RxNorm
MERCK INDEX
m4452
Created by admin on Fri Dec 15 16:39:41 UTC 2023 , Edited by admin on Fri Dec 15 16:39:41 UTC 2023
PRIMARY Merck Index
CHEBI
145796
Created by admin on Fri Dec 15 16:39:41 UTC 2023 , Edited by admin on Fri Dec 15 16:39:41 UTC 2023
PRIMARY
DRUG CENTRAL
881
Created by admin on Fri Dec 15 16:39:41 UTC 2023 , Edited by admin on Fri Dec 15 16:39:41 UTC 2023
PRIMARY
INN
1547
Created by admin on Fri Dec 15 16:39:41 UTC 2023 , Edited by admin on Fri Dec 15 16:39:41 UTC 2023
PRIMARY
DRUG BANK
DB01396
Created by admin on Fri Dec 15 16:39:41 UTC 2023 , Edited by admin on Fri Dec 15 16:39:41 UTC 2023
PRIMARY
EPA CompTox
DTXSID0022933
Created by admin on Fri Dec 15 16:39:41 UTC 2023 , Edited by admin on Fri Dec 15 16:39:41 UTC 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
DIGITOXIN
Created by admin on Fri Dec 15 16:39:41 UTC 2023 , Edited by admin on Fri Dec 15 16:39:41 UTC 2023
PRIMARY Description: A white or almost white, microcrystalline powder; odourless.Solubility: Practically insoluble in water; slightly soluble in ethanol (~750 g/l) TS.Category: Cardiotonic.Storage: Digitoxin should be kept in a well-closed container, protected from light.Additional information: CAUTION: Digitoxin is extremely poisonous and should be handled with care.Requirements: Definition. Digitoxin contains not less than 95.0% and not more than 105.0% of C41H64O13, calculated with reference to the dried substance.
FDA UNII
E90NZP2L9U
Created by admin on Fri Dec 15 16:39:41 UTC 2023 , Edited by admin on Fri Dec 15 16:39:41 UTC 2023
PRIMARY
CAS
71-63-6
Created by admin on Fri Dec 15 16:39:41 UTC 2023 , Edited by admin on Fri Dec 15 16:39:41 UTC 2023
PRIMARY
ChEMBL
CHEMBL254219
Created by admin on Fri Dec 15 16:39:41 UTC 2023 , Edited by admin on Fri Dec 15 16:39:41 UTC 2023
PRIMARY
PUBCHEM
441207
Created by admin on Fri Dec 15 16:39:41 UTC 2023 , Edited by admin on Fri Dec 15 16:39:41 UTC 2023
PRIMARY
SMS_ID
100000092778
Created by admin on Fri Dec 15 16:39:41 UTC 2023 , Edited by admin on Fri Dec 15 16:39:41 UTC 2023
PRIMARY
DAILYMED
E90NZP2L9U
Created by admin on Fri Dec 15 16:39:41 UTC 2023 , Edited by admin on Fri Dec 15 16:39:41 UTC 2023
PRIMARY
CHEBI
28544
Created by admin on Fri Dec 15 16:39:41 UTC 2023 , Edited by admin on Fri Dec 15 16:39:41 UTC 2023
PRIMARY
NCI_THESAURUS
C2634
Created by admin on Fri Dec 15 16:39:41 UTC 2023 , Edited by admin on Fri Dec 15 16:39:41 UTC 2023
PRIMARY
MESH
D004074
Created by admin on Fri Dec 15 16:39:41 UTC 2023 , Edited by admin on Fri Dec 15 16:39:41 UTC 2023
PRIMARY
ECHA (EC/EINECS)
200-760-5
Created by admin on Fri Dec 15 16:39:41 UTC 2023 , Edited by admin on Fri Dec 15 16:39:41 UTC 2023
PRIMARY
NSC
7529
Created by admin on Fri Dec 15 16:39:41 UTC 2023 , Edited by admin on Fri Dec 15 16:39:41 UTC 2023
PRIMARY
WIKIPEDIA
DIGITOXIN
Created by admin on Fri Dec 15 16:39:41 UTC 2023 , Edited by admin on Fri Dec 15 16:39:41 UTC 2023
PRIMARY
IUPHAR
6782
Created by admin on Fri Dec 15 16:39:41 UTC 2023 , Edited by admin on Fri Dec 15 16:39:41 UTC 2023
PRIMARY
RS_ITEM_NUM
1199002
Created by admin on Fri Dec 15 16:39:41 UTC 2023 , Edited by admin on Fri Dec 15 16:39:41 UTC 2023
PRIMARY
EVMPD
SUB07133MIG
Created by admin on Fri Dec 15 16:39:41 UTC 2023 , Edited by admin on Fri Dec 15 16:39:41 UTC 2023
PRIMARY